Latest On-Demand Webinars

Join us for an exclusive panel discussion focused on research and development relating to novel chemical entities in the psychedelics industry and some of the viable business models that are emerging in this field.

This Technology Networks event features exclusive talks focused on the most recent and innovative developments in the world of cell and gene therapies. Our expert speakers will highlight the opportunities cell and gene therapies provide for the treatment of disease and injury, including how cell therapies are providing novel solutions for rare diseases such as Duchenne muscular dystrophy.

A long-standing concern for neuroscientists studying specific cell types in vivo is whether cell isolation from CNS tissue induces ex vivo activational artifacts that confound experimental interpretations.

Alzheimer’s disease is the most common form of neurodegenerative disease, estimated to contribute to 60–70% of all cases of dementia worldwide. Increasing evidence suggests that neuroinflammation, primarily mediated by microglia, contributes to the onset and progression of Alzheimer’s disease.

Join us for an extended webinar focusing on the recent advances in psilocybin research.

Our major findings were that the neural network was able to accurately classify 11 out of 12 leukemia samples, with as little as 5 minutes of sequencing needed to accurately classify ALL.

In order to generate a genomic atlas of protein levels in neurologically relevant tissues, Dr. Carlos Cruchaga and his team profiled thousands of proteins, and performed bioinformatic analyses to determine if any of the identified proteins are drugable.

This webinar explores the use of high-resolution ion mobility performed on the MOBIE platform for the characterization of different lipid classes starting from phosphatidylcholines and gangliosides.

Join us on June 22 with Boris Heifets, MD, PhD, Assistant Professor of the Department of Anesthesiology, Perioperative and Pain Medicine at Stanford University School of Medicine, who will explore the future of psychedelic medicine.

Kevin McKernan, CSO at Medicinal Genomics will be joining us to discuss genetic variation in the Psilocybe cubensis synthesis pathway and the design of qPCR assays for simultaneous quantification of E. coli and Salmonella species contamination concurrent with Psilocybe cubensis species identification.